<DOC>
	<DOCNO>NCT00508664</DOCNO>
	<brief_summary>The DeLOS II trial multicenter randomise phase II trial investigate TP/5-Fluorouracil ( TPF ) -chemotherapy without cetuximab Patients laryngectomy operable carcinoma larynx/hypopharynx . Patients divide responder non-responder 4 week . Since August 2009 Responder receive TP without Cetuximab + radiation . ( Until february 2009 Responder receive TPF without Cetuximab + radiation . ) Planned accrual 85 patient per treatment arm . The primary study endpoint confirmatory proof adequate survival rate functionally larynx-conserving 2 year randomisation .</brief_summary>
	<brief_title>Docetaxel , Cisplatin ( TP ) + Radiation +/- Cetuximab Larynx Carcinoma ( CA )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm , primary laryngectomy respectable squamouscell carcinoma larynx hypopharynx T3T4a carcinoma glottis T2T4a carcinoma supraglottic , controllable laryngectomy applicable root tongue segmental resection T2T4a carcinoma hypopharynx controllable laryngectomy ( example T2 , post cricoidal ) hypopharynx segmental resection Nstatus : cervical metastasis ( N0N3 ) rehabilitate surgical procedure Blood count : Leukocytes &gt; 3500/mm\3 , Neutrophils &gt; 1500/ mm\3 , Thrombocytes &gt; 8000/ mm\3 Clinical chemistry : adequate renal function , define serum creatinine urea high 25 % upper NL , creatinineclearance &gt; 60 ml/min/1,72 m\2 adequate hepatic function SGOT , SGPT high 50 % bilirubin high upper NL electrolytes NL anesthetic risk normal lowgrade elevate age 1875 year write informed consent effective contraception individual advice men woman possibility reproductive potential ( effective contraception : oral contraception estrogen gestagen ( minipill ) , vaginal ring , contraception patch , estrogen free ovulation suppressor , hormone spiral progesterone , injection three month depot gestagen , hormone release implantation ( luteal hormone contain rod ) , abstinence sterilization ( vasectomy ) male ) primary cancer treatable operational larynx conserving procedure distant metastasis ( M1Status ) total tumor volume exceed 80 ml larynx skeleton punctuate infiltration surround soft tissue respectively esophageal aditus ( exclusive cartilage infiltration represent exclusion criterion ) tumorspecific prior chemo radiotherapy metachronous synchronous malignant tumor ( exception basalioma ) [ case control tumor different localization nontreated interval 5 year present therapy patient include consultation coordinate investigator ] life expectancy &lt; 3 month Karnofsky performance status &lt; 70 % serious cardiopulmonary concomitant disease ( cardiac insufficiency grade III IV accord NYHA status , myocardial infarction , angina pectoris , respiratory global insufficiency ) Chronic diseases permanenttherapy ( uncontrolled diabetes , active rheumatoid arthritis ) recurrent pneumonia , COPD GOLD stage &lt; 2 , chronic inflammation intestine concomitant disease , disallow study participation opinion responsible physician Other circumstance ( contraindication ) , disallow treatment Docetaxel , Cisplatin , 5FU , Cetuximab radiotherapy Expected absent patient compliance Periodic followup possible ( example address outside germany ) Pregnant breastfeed woman Absent constrict legal capacity Participation another clinical trial investigational study within 30 day prior study screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>laryngectomy operable carcinoma larynx hypopharynx</keyword>
</DOC>